A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

Exclusion Criteria

• •Have type 1 diabetes mellitus
• •Have had chronic or acute pancreatitis any time prior to study entry
• •Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment
• •Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss
• •Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) enzyme level \>3.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory. Participants with nonalcoholic fatty liver disease (NAFLD) are eligible for participation in this trial only if there ALT level is ≤3.0 the ULN for the reference range
• •Have an estimated glomerular filtration rate \<45 milliliters/minute/1.73 m² (or lower than the country specific threshold for using the protocol required dose of metformin per local label)
• •Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
• •Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
• •Have been taking any other diabetes medicines other than metformin during the last 3 months
• •Have been taking weight loss drugs, including over-the-counter medications during the last 3 months